rss
Thorax 2010;65:379-383 doi:10.1136/thx.2009.125831
  • Cystic fibrosis

Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function

  1. Reshma Amin1,
  2. Padmaja Subbarao1,
  3. Alisha Jabar1,
  4. Susan Balkovec1,
  5. Renee Jensen1,
  6. Shawn Kerrigan1,
  7. Per Gustafsson2,
  8. Felix Ratjen1
  1. 1Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada
  2. 2Department of Paediatrics, Central Hospital, Skövde, Sweden
  1. Correspondence to Dr Reshma Amin, Hospital for Sick Children, 555 University Avenue, Toronto Ontario M5G 1X8, Canada; reshma.amin{at}sickkids.ca
  • Received 21 August 2009
  • Accepted 24 November 2009

Abstract

Background and aims Sensitive outcome measures to assess the efficacy of therapeutic interventions in patients with cystic fibrosis (CF) with mild lung disease are currently lacking. Our objective was to study the ability of the lung clearance index (LCI), a measure of ventilation inhomogeneity, to detect a treatment response to hypertonic saline inhalation in paediatric patients with CF with normal spirometry.

Methods In a crossover trial, 20 patients with CF received 4 weeks of hypertonic saline (HS) and isotonic saline (IS) in a randomised sequence separated by a 4 week washout period. The primary end point was the change in the LCI due to HS versus IS.

Results Baseline characteristics including the LCI were not significantly different between both study periods. Four weeks of twice-daily HS inhalation significantly improved the LCI compared with IS (1.16, 95% CI 0.26 to 2.05; p=0.016), whereas other outcome measures such as spirometry and quality of life failed to reach statistical significance. Randomisation order had no significant impact on the treatment effect.

Conclusions The LCI, but not spirometry was able to detect a treatment effect from HS inhalation in patients with CF with mild disease and may be a suitable tool to assess early intervention strategies in this patient population.

Clinical trial number NCT00635141.

Footnotes

  • Linked articles 132100.

  • RA and PS contributed equally to this work.

  • Funding Canadian Institute of Health Research the Canadian Cystic Fibrosis Foundation-Breathe Program and the Irwin (Arnold and Lynn) family donation.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Ethics Board of the Hospital for Sick Children, and Health Canada.

  • Provenance and peer review Not commissioned; externally peer reviewed.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. Files in this Data Supplement

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Thorax.
View free sample issue >>

Free archive
The full back archive is now available for Thorax. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.